Merck & Co., Inc.
Merck Reports First-Quarter 2025 Financial Results
Summary
Merck & Co., Inc. reported first-quarter 2025 financial results, showing total worldwide sales of $15.5 billion, a 2% decrease from the prior year. GAAP EPS was $2.01, and non-GAAP EPS was $2.22. Keytruda sales grew by 4%, while Gardasil/Gardasil 9 sales declined by 41%. Merck also presented pivotal data from various clinical trials and provided a full-year 2025 financial outlook.
Profitelligence Alerts
Get alerts for MRK
Be first to know when Merck & Co., Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Official SEC Documents
Advertisement